EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study

Dritte-Generation-EGFR-TKIs kombiniert mit Chemotherapie bei fortgeschrittenem nicht-kleinzelligem Lungenkarzinom: Real-World-Studie

YuQin Jiang, Qi Liang iD, Yuting Zhu, Xiao Liang, Ruohan Huang, Wenxin Zhou, Chen Zhang, Jun Li, Jiali Xu, Renhua Guo iD

Cancer Science · 2026-02 · 117 (2) · 476-490

DOI: 10.1111/cas.70269 ↗

Auf einen Blick

Bei 382 Patient:innen mit fortgeschrittenem EGFR-mutiertem NSCLC waren Drittgeneration-EGFR-TKIs plus Chemotherapie mit median 30,9 Monaten PFS und 53,9 Monaten OS verbunden. Die ORR lag bei 76,4 %.

Fragestellung

Wie wirksam, sicher und mit welchem Progressionsmuster sind Drittgeneration-EGFR-TKIs plus Chemotherapie bei fortgeschrittenem EGFR-mutiertem NSCLC im Versorgungsalltag?

Methode

Retrospektive, monozentrische Beobachtungsstudie im Real-World-Setting; 382 Patient:innen mit Erstlinientherapie aus Juli 2016 bis Mai 2024.

Ergebnisse

Medianes Follow-up 34,6 Monate (95 %-KI 32,2–35,6), medianes PFS 30,9 Monate (95 %-KI 27,5–39,3), medianes OS 53,9 Monate (95 %-KI 46,2–NR). ORR 76,4 %, DCR 98,2 %, 35,9 % mit Grad-3-oder-höheren AEs. Zwischen den TKI-Gruppen kein signifikanter PFS-Unterschied (HR 0,75; 95 %-KI 0,51–1,10).

Schlussfolgerung der Autor:innen

Die Erstlinienkombination aus Drittgeneration-EGFR-TKI und pemetrexedbasierter Chemotherapie zeigte bei fortgeschrittenem EGFR-mutiertem NSCLC eine günstige ORR und einen PFS-Vorteil.

Kernaussagen

  • 382 Patient:innen in einer retrospektiven Real-World-Studie
  • Medianes PFS 30,9 Monate; medianes OS 53,9 Monate
  • Keine signifikanten Unterschiede zwischen den TKI-Gruppen beim PFS

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Science, online erschienen am 28.11.2025. Verfasst von YuQin Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital With Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Important Talents of Jiangsu Province, National Natural Science Foundation of China, Graduate Research and Innovation Projects of Jiangsu Province.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FLAURA2 has demonstrated that third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) plus chemotherapy brought a significant survival benefit over EGFR‐TKI monotherapy. This suggests that EGFR‐TKIs combined with chemotherapy may be a viable therapeutic strategy. Our study aimed to evaluate the efficacy, safety, and progression pattern of third‐generation EGFR‐TKIs combined with chemotherapy in advanced EGFR ‐mutant ( EGFR m) non‐small cell lung cancer (NSCLC) in the real world. This study designed as an observational, retrospective, single‐center, real‐world project enrolled 382 NSCLC individuals receiving third‐generation EGFR‐TKIs combined with platinum‐based chemotherapy as first‐line therapy. The primary end point was progression‐free survival (PFS), and secondary end points included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). From July 2016 to May 2024, 382 patients were retrospectively included for the analysis. Of these patients, 120, 165, and 97 patients received osimertinib, aumolertinib, and furmonertinib plus chemotherapy as first‐line therapy, respectively. Overall, the median follow‐up duration was 34.6 months (95% CI: 32.2–35.6), the median PFS was 30.9 months (95% CI: 27.5–39.3), and the median OS was 53.9 months (95% CI: 46.2–NR). Overall, the ORR was 76.4% and the DCR was 98.2%. One hundred thirty‐seven (35.9%) individuals experienced Grade 3 or higher AEs. Different third‐generation EGFR‐TKI groups show no statistically significant difference in PFS (HR = 0.75; 95% CI: 0.51–1.10; p = 0.25) after inverse probability of treatment weighting (IPTW), nor in AEs or severe AEs ( p = 0.852; p = 0.502). First‐line third‐generation EGFR‐TKI combined with pemetrexed‐based chemotherapy demonstrated a favorable ORR and PFS benefit in advanced EGFR m NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsHumansFemaleMaleErbB ReceptorsMiddle AgedAgedRetrospective StudiesAdultAcrylamidesMutationProgression-Free SurvivalAniline CompoundsAged, 80 and overTreatment OutcomeIndolesPyrimidines

Stichwörter der Autor:innen

EGFRmadvanced NSCLCplatinum‐based chemotherapyreal‐worldthird‐generation EGFR‐TKIs

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanAcrylamidesosimertinibAniline CompoundsIndolesPyrimidines

Autor:innen und Institutionen

  • The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
  • Department of Oncology, Jiangyin Clinical College of Xuzhou Medical University, Xuzhou, China.

ORCID-Profile: Qi Liang, Renhua Guo

Förderung

  • Medical Important Talents of Jiangsu Province
  • National Natural Science Foundation of China
  • Graduate Research and Innovation Projects of Jiangsu Province
  • Cancer Foundation of China

Zitieren

APA

Jiang, Y., Liang, Q., Zhu, Y., Liang, X., Huang, R., Zhou, W., Zhang, C., Li, J., Xu, J., & Guo, R. (2026). Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study. Cancer Science, 117(2), 476-490. https://doi.org/10.1111/cas.70269

Vancouver

Jiang Y, Liang Q, Zhu Y, Liang X, Huang R, Zhou W, et al. Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study. Cancer Science. 2026;117(2):476-490. doi:10.1111/cas.70269

BibTeX
@article{Jiang2026,
  author = {Jiang, YuQin and Liang, Qi and Zhu, Yuting and Liang, Xiao and Huang, Ruohan and Zhou, Wenxin and Zhang, Chen and Li, Jun and Xu, Jiali and Guo, Renhua},
  title = {Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {2},
  pages = {476--490},
  doi = {10.1111/cas.70269}
}
Kostenlos starten →